285 related articles for article (PubMed ID: 30417521)
41. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
42. Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis.
Chen CY; Chou WC; Tsay W; Tang JL; Yao M; Huang SY; Tien HF
BMC Cancer; 2013 Mar; 13():107. PubMed ID: 23496932
[TBL] [Abstract][Full Text] [Related]
43. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract][Full Text] [Related]
44. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry.
Tettero JM; Dakappagari N; Heidinga ME; Oussoren-Brockhoff Y; Hanekamp D; Pahuja A; Burns K; Kaur P; Alfonso Z; van der Velden VHJ; Te Marvelde JG; Hobo W; Slomp J; Bachas C; Kelder A; Nguyen K; Cloos J
Cytometry B Clin Cytom; 2023 Nov; 104(6):426-439. PubMed ID: 37766649
[TBL] [Abstract][Full Text] [Related]
45. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
46. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia.
Suzuki T; Kiyoi H; Ozeki K; Tomita A; Yamaji S; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Ueda R; Kinoshita T; Emi N; Naoe T
Blood; 2005 Oct; 106(8):2854-61. PubMed ID: 15994285
[TBL] [Abstract][Full Text] [Related]
48. Nucleophosmin gene mutations in acute myeloid leukemia.
Chen W; Rassidakis GZ; Medeiros LJ
Arch Pathol Lab Med; 2006 Nov; 130(11):1687-92. PubMed ID: 17076533
[TBL] [Abstract][Full Text] [Related]
49. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
50. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
51. Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.
Khanna-Gupta A; Abayasekara N; Levine M; Sun H; Virgilio M; Nia N; Halene S; Sportoletti P; Jeong JY; Pandolfi PP; Berliner N
J Biol Chem; 2012 Sep; 287(39):32728-37. PubMed ID: 22851180
[TBL] [Abstract][Full Text] [Related]
52. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Kern W; Voskova D; Schoch C; Hiddemann W; Schnittger S; Haferlach T
Blood; 2004 Nov; 104(10):3078-85. PubMed ID: 15284114
[TBL] [Abstract][Full Text] [Related]
53. Measurable Residual
Gui G; Dillon LW; Ravindra N; Hegde PS; Andrew G; Mukherjee D; Wong Z; Auletta J; El Chaer F; Chen E; Chen YB; Corner A; Devine SM; Iyer S; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Spellman SR; Zeger SL; Page KM; Hourigan CS
medRxiv; 2023 Aug; ():. PubMed ID: 37577695
[TBL] [Abstract][Full Text] [Related]
54. Acute Myeloid Leukemia with Myelodysplasia - Related Changes after Isolated Myeloid Sarcoma.
Li X; Yin J; Li L
Clin Lab; 2024 May; 70(5):. PubMed ID: 38747915
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH; van der Sluijs-Geling A; Gibson BE; te Marvelde JG; Hoogeveen PG; Hop WC; Wheatley K; Bierings MB; Schuurhuis GJ; de Graaf SS; van Wering ER; van Dongen JJ
Leukemia; 2010 Sep; 24(9):1599-606. PubMed ID: 20668473
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach.
Petiti J; Pignochino Y; Schiavon A; Giugliano E; Berrino E; Giordano G; Itri F; Dragani M; Cilloni D; Lo Iacono M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612443
[TBL] [Abstract][Full Text] [Related]
57. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T; Al Hinai ASA; Sanders MA; Kavelaars FG; Rijken M; Gradowska PL; Biemond BJ; Breems DA; Maertens J; van Marwijk Kooy M; Pabst T; de Weerdt O; Ossenkoppele GJ; van de Loosdrecht AA; Huls GA; Cornelissen JJ; Beverloo HB; Löwenberg B; Jongen-Lavrencic M; Valk PJM
Blood; 2022 Apr; 139(15):2347-2354. PubMed ID: 35108372
[TBL] [Abstract][Full Text] [Related]
58. Abnormal B-lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia.
Chan A; Kumar P; Gao Q; Baik J; Sigler A; Londono D; Liu Y; Arcila ME; Dogan A; Zhang Y; Roshal M; Xiao W
Cytometry B Clin Cytom; 2023 May; 104(3):243-252. PubMed ID: 34897961
[TBL] [Abstract][Full Text] [Related]
59. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
Schnittger S; Haferlach C; Ulke M; Alpermann T; Kern W; Haferlach T
Blood; 2010 Dec; 116(25):5486-96. PubMed ID: 20805365
[TBL] [Abstract][Full Text] [Related]
60. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
Falini B; Nicoletti I; Martelli MF; Mecucci C
Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
